Johnson & Johnson vaccine 66% effective in global trials, company says
Local
Johnson and Johnson have reportedly developed a single-shot COVID-19 vaccine which the company has reported to be 66% against moderate and severe illness in the third phase of their global trials.
They went on to report that the vaccine is 85% effective against the most serious symptoms, with many countries around the world in desperate need for more vaccines.
As stated by Johnson & Johnson’s vaccine branch, Janssen, the vaccine’s 85% efficacy prevents severe diseases, that is, ones that “make you feel particularly sick at home, or may go to the hospital, or worse..”
#MaltaDaily